BeyondSpring — Third Quarter 2026 Earnings Summary

BeyondSpring Inc. reported a net loss of $2.1 million for the third quarter ended September 30, 2026, driven by increased research and development and general and administrative expenses. The company received FDA Fast Track designation for its lead candidate Plinabulin combined with docetaxel in patients with post-immunotherapy non-squamous non-small cell lung cancer lacking actionable genomic alterations. A strategic transaction with Biolin Investment Limited was completed to fund approximately half of the DUBLIN-4 Phase 3 trial's patient enrollment in China, providing BeyondSpring with access to the resulting clinical data. As of September 30, 2026, the company held $0.6 million in cash, cash equivalents, and short-term investments.